They focus on inflammation reduction (IL-6 and IL-8), immune system failure (by blocking CTLA-4 and PD-1 receptors on unresponsive T-cells), invasion and metastasis (by anti-mesothelin as well as anti-CD13 expressed on tumor endothelium), but also angiogenesis (via an anti-VEGF approach) as well as direct cell death (by HDAC inhibitors, which induce tumor-cell-selective expression of pro-apoptotic genes). Here, MSLN is linked to neoplasm.